Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA TAXANE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL_ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
6.1 CONCLUSION
7 MIDDLE EAST & AFRICA TAXANE MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN INCIDENCE OF CANCER
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS
8.1.4 USE OF REIMBURSEMENT FOR TAXANE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT
8.2.3 RISE IN PRODUCT RECALLS
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT
9 MIDDLE EAST & AFRICA TAXANE MARKET, BY TYPE
9.1 OVERVIEW
9.2 PACLITAXEL
9.2.1 BY TYPE
9.2.1.1 SEMI-SYNTHETIC
9.2.1.2 NATURAL
9.2.2 BY STRENGTH
9.2.2.1 100MG
9.2.2.2 200MG
9.2.2.3 250MG
9.2.2.4 30MG
9.2.2.5 260MG
9.2.2.6 300MG
9.3 DOCETAXEL
9.3.1 120MG
9.3.2 80MG
9.3.3 20MG
9.3.4 40MG
9.3.5 60MG
9.4 CABAZITAXEL
9.4.1 60MG
10 MIDDLE EAST & AFRICA TAXANE MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 BREAST CANCER
10.3 NON-SMALL CELL LUNG CANCER
10.4 PANCREATIC CANCER
10.5 OVARIAN CANCER
10.6 PROSTATE CANCER
10.7 OTHERS
11 MIDDLE EAST & AFRICA TAXANE MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERICS
11.3 BRANDED
12 MIDDLE EAST & AFRICA TAXANE MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 LIPOSOMES
12.3 NANOPARTICLES
12.4 POLYMERIC MICELLES
12.5 OTHERS
13 MIDDLE EAST & AFRICA TAXANE MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.2.1 FEMALE
13.2.2 MALE
13.3 GERIATRIC
13.3.1 FEMALE
13.3.2 MALE
14 MIDDLE EAST & AFRICA TAXANE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 AMBULATORY SURGICAL CENTERS
14.4 SPECIALTY CLINICS
14.5 OTHERS
15 MIDDLE EAST & AFRICA TAXANE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 HOSPITAL PHARMACY
15.2.2 RETAIL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
16 MIDDLE EAST & AFRICA TAXANE MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 EGYPT
16.1.3 SAUDI ARABIA
16.1.4 U.A.E
16.1.5 ISRAEL
16.1.6 KUWAIT
16.1.7 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST & AFRICA TAXANE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BRISTOL-MYERS SQUIBB COMPANY
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 SANOFI-AVENTIS U.S. LLC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA )
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 HIKMA PHARMACEUTICALS PLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ACCORD HEALTHCARE
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AQVIDA GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 AUREATE HEALTHCARE
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 DR. REDDY’S LABORATORIES LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 ELEVAR THERAPEUTICS
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENTS
19.13 HETERO HEALTHCARE LIMITED.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 HUIANG PHARMACEUTICAL CO LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 INGENUS PHARMACEUTICALS, LLC
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 LUYE PHARMA GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 PANACEA BIOTEC
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 RPG LIFE SCIENCES LIMITED
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SAMARTH LIFE SCIENCES PVT. LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 SAMYANG HOLDINGS CORPORATION.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 TORRENT PHARMACEUTICALS LTD
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 TAXANE HEALTHCARE
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST & AFRICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA PACLITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA DOCETAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA CABAZITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA BREAST CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA NON-SMALL LUNG CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA PANCREATIC CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA OVARIAN CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA PROSTATE CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA GENERICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA BRANDED IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA LIPOSOMES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA NANOPARTICLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA POLYMERIC MICELLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA ADULT IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA GERIATRIC IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA HOSPITALS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA RETAIL SALES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA DIRECT TENDER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA TAXANE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 57 SOUTH AFRICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 SOUTH AFRICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 59 SOUTH AFRICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 SOUTH AFRICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 63 SOUTH AFRICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 64 SOUTH AFRICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 SOUTH AFRICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 SOUTH AFRICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 EGYPT TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 EGYPT PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 EGYPT TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 EGYPT TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 EGYPT TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 72 EGYPT PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 73 EGYPT DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 74 EGYPT CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 75 EGYPT TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 76 EGYPT ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 77 EGYPT GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 78 EGYPT TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 EGYPT TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 EGYPT RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 SAUDI ARABIA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 SAUDI ARABIA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 SAUDI ARABIA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 SAUDI ARABIA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 85 SAUDI ARABIA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 86 SAUDI ARABIA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 87 SAUDI ARABIA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 88 SAUDI ARABIA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 89 SAUDI ARABIA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 90 SAUDI ARABIA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 91 SAUDI ARABIA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 92 SAUDI ARABIA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 SAUDI ARABIA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 SAUDI ARABIA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 U.A.E TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 U.A.E PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 U.A.E TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 98 U.A.E TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 99 U.A.E TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 100 U.A.E PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 101 U.A.E DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 102 U.A.E CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 103 U.A.E TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 104 U.A.E ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 105 U.A.E GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 106 U.A.E TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 107 U.A.E TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 108 U.A.E RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 109 ISRAEL TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 ISRAEL PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 ISRAEL TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 112 ISRAEL TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 113 ISRAEL TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 114 ISRAEL PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 115 ISRAEL DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 116 ISRAEL CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 117 ISRAEL TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 118 ISRAEL ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 119 ISRAEL GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 120 ISRAEL TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 121 ISRAEL TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 122 ISRAEL RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 KUWAIT TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 KUWAIT PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 KUWAIT TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 126 KUWAIT TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 127 KUWAIT TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 128 KUWAIT PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 129 KUWAIT DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 130 KUWAIT CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 131 KUWAIT TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 132 KUWAIT ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 133 KUWAIT GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 134 KUWAIT TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 135 KUWAIT TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 136 KUWAIT RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 137 REST OF MIDDLE EAST AND AFRICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST & AFRICA TAXANE MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA TAXANE MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA TAXANE MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA TAXANE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA TAXANE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA TAXANE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA TAXANE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA TAXANE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA TAXANE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA TAXANE MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE MIDDLE EAST & AFRICA TAXANE MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INVESTMENT FOR HEALTHCARE INFRASTRUCTURE IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA TAXANE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA TAXANE MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA TAXANE MARKET
FIGURE 15 INCIDENCE OF BREAST CANCER IN 2020
FIGURE 16 MIDDLE EAST & AFRICA TAXANE MARKET: BY TYPE, 2021
FIGURE 17 MIDDLE EAST & AFRICA TAXANE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA TAXANE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 MIDDLE EAST & AFRICA TAXANE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA TAXANE MARKET: BY APPLICATION, 2021
FIGURE 21 MIDDLE EAST & AFRICA TAXANE MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA TAXANE MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 23 MIDDLE EAST & AFRICA TAXANE MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA TAXANE MARKET: BY DRUG TYPE, 2021
FIGURE 25 MIDDLE EAST & AFRICA TAXANE MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA TAXANE MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 MIDDLE EAST & AFRICA TAXANE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA TAXANE MARKET: BY FORMULATION, 2021
FIGURE 29 MIDDLE EAST & AFRICA TAXANE MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA TAXANE MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 MIDDLE EAST & AFRICA TAXANE MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 MIDDLE EAST & AFRICA TAXANE MARKET: BY AGE GROUP, 2021
FIGURE 33 MIDDLE EAST & AFRICA TAXANE MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 34 MIDDLE EAST & AFRICA TAXANE MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 35 MIDDLE EAST & AFRICA TAXANE MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 36 MIDDLE EAST & AFRICA TAXANE MARKET: BY END USER, 2021
FIGURE 37 MIDDLE EAST & AFRICA TAXANE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 38 MIDDLE EAST & AFRICA TAXANE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 MIDDLE EAST & AFRICA TAXANE MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST & AFRICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 MIDDLE EAST & AFRICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 42 MIDDLE EAST & AFRICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 MIDDLE EAST & AFRICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST AND AFRICA TAXANE MARKET: SNAPSHOT (2021)
FIGURE 45 MIDDLE EAST AND AFRICA TAXANE MARKET: BY COUNTRY (2021)
FIGURE 46 MIDDLE EAST AND AFRICA TAXANE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 MIDDLE EAST AND AFRICA TAXANE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 MIDDLE EAST AND AFRICA TAXANE MARKET: BY TYPE (2022-2029)
FIGURE 49 MIDDLE EAST & AFRICA TAXANE MARKET: COMPANY SHARE 2021 (%)
